PT-141

Overview

PT-141, known generically as bremelanotide and sold under the brand name Vyleesi, is a melanocortin receptor agonist developed to treat low sexual desire. Unlike treatments that act on blood flow, it works through pathways in the central nervous system involved in sexual motivation.

PT-141 is FDA-approved. It is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, a condition defined by persistent, distressing low sexual desire that is not explained by another medical or psychiatric cause, relationship problems, or medication effects.

It is administered as a subcutaneous injection taken before anticipated sexual activity rather than on a daily schedule. Because it is an approved prescription product, it is dispensed through licensed healthcare providers, which distinguishes it sharply from the many unapproved research-chemical peptides sold online. This regulatory approval reflects a completed clinical development program.

How it works

Bremelanotide is a synthetic analog of a naturally occurring hormone fragment and acts as an agonist at melanocortin receptors, with activity at the MC4 receptor considered central to its effect on sexual desire. These receptors are located in regions of the brain that help regulate sexual motivation and arousal.

This central mechanism is what sets PT-141 apart from drugs such as PDE5 inhibitors, which work peripherally by increasing genital blood flow. Bremelanotide instead targets the neural circuitry of desire, which is why it is studied specifically for disorders of low desire rather than purely physical arousal problems.

Because melanocortin receptors also influence pigmentation, appetite, and cardiovascular function, activating them can produce effects beyond the intended one. This explains some of the characteristic side effects seen with the drug, including nausea, flushing, and transient increases in blood pressure. The same receptor family is the reason related unapproved compounds can cause skin darkening.

Clinical evidence

Bremelanotide's approval was supported by a structured clinical development program, including the pivotal Phase 3 trials known by the program name RECONNECT. These randomized, placebo-controlled studies evaluated premenopausal women with HSDD and assessed changes in sexual desire and in the distress associated with low desire.

The trials used validated questionnaires as their main outcome measures rather than counts of sexual events. On these measures, women receiving bremelanotide reported improvements in desire and reductions in related distress compared with placebo. The benefit, while statistically demonstrated, was modest, and not every participant responded.

This evidence base is what allowed regulators to approve the drug for a specific population. It is important to frame the results honestly: PT-141 is not a guaranteed or dramatic fix, and the studies were conducted in a defined group — premenopausal women with diagnosed HSDD — so the findings do not automatically extend to other populations or to general use for libido enhancement.

Dosing & side effects

PT-141 is a prescription medication, and decisions about whether it is appropriate, and how it should be used, must be made with a licensed healthcare provider who can review the full prescribing information. No specific doses or self-administration instructions are provided here, and it should only be used as directed by a clinician.

The most commonly reported side effects in clinical use include nausea (which can be significant), flushing, headache, and reactions at the injection site. Some people also experience temporary darkening of the skin or gums, reflecting the compound's melanocortin activity.

A notable cardiovascular consideration is a transient rise in blood pressure with a corresponding fall in heart rate after dosing. For this reason, the drug is generally not recommended for people with uncontrolled high blood pressure or known cardiovascular disease. The official labeling also advises limits on how often it is used within a given period, which is another reason medical supervision is essential.

Legal status

PT-141 / bremelanotide holds a distinct legal position compared with most peptides discussed in this encyclopedia: it is an FDA-approved prescription drug marketed as Vyleesi. This means it has passed the agency's review for safety and efficacy for its approved indication and is manufactured to pharmaceutical quality standards.

Because it is a prescription product, it should be obtained through a licensed provider and pharmacy. Bremelanotide sold as a research chemical or peptide powder online is a different matter — such products are unregulated, may not be pure or accurately dosed, and fall outside the approved medical framework, even though they share the same chemical name.

Approval status can vary by country, so availability and the exact regulatory category differ between regions. Anyone interested in PT-141 should pursue it through legitimate medical channels rather than the gray market, both for safety and to ensure they are receiving a properly manufactured product under appropriate supervision.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019. Peer-reviewed study
2. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003. Peer-reviewed study
3. Hedlund P. PT-141 Palatin. Curr Opin Investig Drugs. 2004. Peer-reviewed study
4. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019. Peer-reviewed study
5. Diamond LE, Earle DC, Garcia WD, et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005. Peer-reviewed study
6. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. Peer-reviewed study